Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $33.39, but opened at $32.42. Amphastar Pharmaceuticals shares last traded at $33.20, with a volume of 79,754 shares trading hands.
Analyst Upgrades and Downgrades
Several brokerages recently commented on AMPH. Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $66.00 to $36.00 in a research note on Tuesday. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price objective on the stock. Finally, StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $50.33.
View Our Latest Report on AMPH
Amphastar Pharmaceuticals Stock Performance
The company's 50-day moving average price is $38.39 and its 200 day moving average price is $43.73. The stock has a market capitalization of $1.56 billion, a PE ratio of 10.79, a PEG ratio of 1.07 and a beta of 0.81. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.
Insiders Place Their Bets
In other news, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the transaction, the executive vice president now directly owns 118,469 shares in the company, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard K. Prins sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total value of $244,000.00. Following the completion of the sale, the director now owns 31,471 shares in the company, valued at $1,535,784.80. The trade was a 13.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,893 shares of company stock worth $1,329,570 over the last three months. Company insiders own 27.10% of the company's stock.
Institutional Investors Weigh In On Amphastar Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the stock. Aurora Investment Counsel increased its position in shares of Amphastar Pharmaceuticals by 0.4% during the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company's stock valued at $2,654,000 after acquiring an additional 232 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after buying an additional 273 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock worth $85,000 after buying an additional 301 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its stake in Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after acquiring an additional 398 shares during the period. Finally, nVerses Capital LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 18.2% during the 3rd quarter. nVerses Capital LLC now owns 2,600 shares of the company's stock valued at $126,000 after acquiring an additional 400 shares during the last quarter. 65.09% of the stock is owned by institutional investors.
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Further Reading
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
